J Code for Glucagon: Product Composition and Key Specifications
Published: July 18, 2026 14:59
Author: Michael Hoffmann
Abstract: Glucagon’s J-code (J1610) designates a critical therapeutic peptide for severe hypoglycemia. This analysis contrasts recombinant (GlucaGen, Baqsimi) vs. synthetic analogs, highlighting nasal vs. injectable delivery. Market data (CAGR 8.5% to 2030) underscores rising demand. Key specifications include purity (>98% by HPLC) and stability (36-month shelf life). Product comparison reveals trade-offs: injection offers precise dosing but requires reconstitution; nasal powder ensures rapid absorption but has higher cost. Selection criteria prioritize FDA/EMA certification, cold-chain logistics (2-8°C), and manufacturer GMP audits. Industry trends favor ready-to-use formats and biosimilar competition.